{"a":[{"_":"Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’","$":{"href":"/biotech/novartis-drops-phase-2-stage-radioligand-therapy-commitment-modality-unchanged","hreflang":"en"}}]}

Phase 2negativeNegative

AI Analysis

Summary

Novartis discontinued a Phase 2 radioligand therapy candidate after disappointing clinical results, though the company remains committed to the radioligand therapy modality overall.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Phase 2-stage radioligand therapy candidate disappointed in clinical trial

Importance:5/10

Sentiment:

-0.60

radioligand therapyphase 2 discontinuationclinical failure

Related Companies

$NVS

Read the original article

Published by FierceBiotech on July 21, 2026 7:47 AM

Read Original